AMPK (AMP-Activated Protein Kinase)

What it is

AMPK is a heterotrimeric kinase that senses the AMP:ATP ratio. When ATP drops, AMP rises, and AMPK is activated. It then phosphorylates substrates that turn off energy-consuming processes (protein synthesis, lipogenesis) and turn on energy-producing ones (fatty-acid oxidation, mitochondrial biogenesis, autophagy).

Why it matters in aging

AMPK activity declines with age. Reactivation through caloric restriction, exercise, or pharmacological agonists (metformin, AICAR) opposes many hallmarks of aging: it suppresses mTOR, promotes autophagy, improves insulin sensitivity, and increases mitochondrial quality.

Activators

• Metformin (indirect, via complex I inhibition).
• Exercise (direct, via ATP demand).
• Caloric restriction and fasting.
• Berberine (modest data).
• Salicylates / aspirin (in vitro).

Cross-talk

• Inhibits mTORC1 via TSC2 phosphorylation and direct Raptor phosphorylation.
• Activates autophagy via ULK1.
• Activates PGC-1α for mitochondrial biogenesis (where applicable).
• Activates SIRT1 by raising NAD⁺.

Longevity relevance

AMPK (AMP-activated protein kinase) is the master cellular energy-status sensor. Its activation is a common downstream node of essentially every intervention that has demonstrated longevity benefit in mammals: caloric restriction, exercise, metformin, resveratrol, and berberine all converge on AMPK activation.

Regulation

• Direct activators: rising AMP:ATP ratio (energy stress).
• Indirect activators:
  • LKB1 (upstream kinase).
  • CaMKKβ (calcium-mediated).
  • Metformin (via mitochondrial complex I inhibition).
  • Resveratrol and other polyphenols.

Downstream effects

• Catabolic activation: fatty-acid oxidation, glucose uptake, autophagy.
• Anabolic suppression: mTORC1 inhibition (TSC2 phosphorylation and Raptor phosphorylation).
• Transcriptional programs: PGC-1α, FOXO, SIRT1 activation.

Interventions

• Exercise: the most powerful and safe AMPK activator.
• Caloric restriction and fasting: reliable AMPK activation.
• Metformin: pharmacologic AMPK activator via mitochondrial complex I inhibition.
• Direct AMPK activators (small molecules like PF-06409577) in preclinical and early clinical development.

Trade-offs

Constitutively-hyperactive AMPK is not benign — see the PRKAG2 syndrome. Sustained modest activation appears beneficial; pathologic hyperactivation causes cardiac and metabolic disease.

Related entries

Metformin, Caloric restriction, Exercise, mTOR, PRKAG2.

Related entries

mTOR, Sirtuins, NAD+ precursors.